menu
    • menu
    [{"orgOrder":0,"company":"Crown Bioscience","sponsor":"HanX Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"HX009","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Crown Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Crown Bioscience \/ Crown Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"Crown Bioscience \/ Crown Bioscience"},{"orgOrder":0,"company":"Crown Bioscience","sponsor":"ERS Genomics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Crown Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Crown Bioscience \/ ERS Genomics","highestDevelopmentStatusID":"3","companyTruncated":"Crown Bioscience \/ ERS Genomics"}]

    Find Clinical Drug Pipeline Developments & Deals by Crown Bioscience

    Menu

    Crown Bioscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Crown Bioscience

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Crown Bioscience

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HX009,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : HanX Biopharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Crown Bioscience Enables HanX Biopharmaceutical to Progress HX009 to Clinical Trials

                            Details : HX009 is the global first-in-class bispecific PD-1/CD47 antibody developed by HanxBio. Phase I clinical studies have been conducted in Australia and China. The company is expanding the next phase clinical development globally in various clinical indicati...

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            August 25, 2023

                            Lead Product(s) : HX009,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : HanX Biopharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Crown Bioscience

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Crown Bioscience

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : ERS Genomics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Crown Bioscience and ERS Genomics Announce Global CRISPR/Cas9 Licensing Agreement for Genome Editing Patents

                            Details : Under the agreement, Crown Bioscience will expand its gene editing capabilities and investigate the prospect of gene editing in 3D patient-derived tumor organoid models.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 12, 2022

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : ERS Genomics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth